GlycoMimetics signs commercial manufacturing deal with Thermo Fisher's Patheon for uproleselan

CRESCENT BIOPHARMA, INC.

Agreement covers commercial supply of injectable uproleselan if FDA approves the drug.
Initial term through Dec 31, 2026, auto-renews for 3-year periods unless terminated.
Company provides API; Patheon supplies other raw materials, packaging, and QC testing.
Company gave Patheon a forecast of required annual volumes through 2027.
Either party may terminate after initial term with 18 months' notice; termination fees apply.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CRESCENT BIOPHARMA, INC. entered into Project Agreement with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific (effective 2024-01-02).

Action: entry
Agreement: supply
Counterparty: Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific
Effective: 2024-01-02

Exact text from the filing

On January 2, 2024, GlycoMimetics, Inc. (the “ Company ”) entered into a project agreement (the “ Project Agreement ”) with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific (“ Patheon ”), pursuant to which Patheon will manufacture and supply the Company with its drug candidate, uproleselan, for commercial sale should the Company receive marketing approval from the U.S. Food and Drug Administration.

View on SEC.gov

242 material agreements filed in the last 30 days. Browse all material agreements →

CRESCENT BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.